Compare
GLP-1 MedicationsGLP-1 Medications

GLP-1 medications work by mimicking the GLP-1 hormone, which helps regulate blood sugar and appetite. The main differences are: (1) Mechanism of action - some are pure GLP-1 agonists (Ozempic, Wegovy, Saxenda, Rybelsus) while others are dual agonists (Mounjaro, Zepbound target both GIP and GLP-1) or triple agonists (Retatrutide targets GLP-1, GIP, and glucagon). (2) Weight loss effectiveness - dual and triple agonists tend to show higher average weight loss. (3) Administration - most are weekly injections, but Rybelsus is a daily oral tablet and Saxenda is a daily injection. (4) FDA approval - some are approved for diabetes, others for weight loss, and some for both.

Based on clinical trials, Retatrutide (investigational) shows the highest average weight loss at 24-27%, followed by Zepbound (tirzepatide) at 20-25%, Mounjaro (tirzepatide) at 15-22%, Wegovy (semaglutide) at 15-17%, Ozempic (semaglutide) at 10-15%, Rybelsus (oral semaglutide) at 8-12%, and Saxenda (liraglutide) at 5-10%. However, individual results vary significantly based on factors like genetics, metabolism, adherence, diet, exercise, and other medications. The 'best' medication depends on your individual response, side effect tolerance, insurance coverage, and provider recommendation.

Yes, many people switch between GLP-1 medications, but this should always be done under medical supervision. Common reasons for switching include: side effects, insufficient weight loss, insurance coverage changes, or preference for different dosing schedules. Your healthcare provider will determine the appropriate transition plan, which may involve tapering off one medication before starting another, or a direct switch depending on the medications involved. Never switch medications without consulting your provider.

The most common side effects across GLP-1 medications include nausea, vomiting, diarrhea, constipation, decreased appetite, and sometimes fatigue. These are typically most pronounced when starting the medication or increasing doses, and often improve over time as your body adjusts. More serious but rare side effects can include pancreatitis, gallbladder problems, kidney issues, and severe allergic reactions. If you experience severe or persistent side effects, contact your healthcare provider immediately. Starting at the lowest dose and gradually increasing helps minimize side effects.

Choosing the right GLP-1 medication involves several factors: (1) Your primary goal - diabetes management vs. weight loss, (2) Insurance coverage and cost, (3) Side effect tolerance, (4) Preference for injection vs. oral administration, (5) Dosing frequency preference (daily vs. weekly), (6) Your provider's recommendation based on your medical history, and (7) Availability and supply issues. There's no one-size-fits-all answer - the best medication is the one that works for you, fits your lifestyle, and is sustainable long-term. Discuss all options with your healthcare provider.

Compounded GLP-1 medications use the same active ingredients (semaglutide or tirzepatide) as brand-name medications, so they have identical pharmacokinetics and should work the same way. However, there are important considerations: (1) Quality control - compounding pharmacies vary in quality and oversight, (2) Purity and consistency - brand-name medications have strict FDA manufacturing standards, (3) Cost - compounded versions are often cheaper but may not be covered by insurance, (4) Safety - ensure your compounding pharmacy is reputable and licensed, (5) Legal status - compounding regulations vary by state. Always discuss compounded options with your healthcare provider and ensure you're using a licensed, reputable compounding pharmacy.

Ozempic and Wegovy both contain the same active ingredient (semaglutide) but are FDA-approved for different uses: Ozempic is approved for type 2 diabetes management, while Wegovy is approved specifically for chronic weight management. The main differences are: (1) Maximum dose - Ozempic goes up to 2 mg, while Wegovy goes up to 2.4 mg, (2) Indication - Ozempic for diabetes, Wegovy for weight loss, (3) Insurance coverage - often different based on your diagnosis, (4) Cost - Wegovy is typically more expensive. Some people use Ozempic off-label for weight loss, but Wegovy is specifically approved and dosed for that purpose.

Mounjaro and Zepbound are the same medication (tirzepatide) but approved for different uses: Mounjaro is FDA-approved for type 2 diabetes management, while Zepbound is approved for chronic weight management. They contain identical active ingredients and have the same dosing schedule (weekly injections, starting at 2.5 mg, up to 15 mg). The differences are primarily: (1) FDA indication - Mounjaro for diabetes, Zepbound for weight loss, (2) Insurance coverage - often different based on your diagnosis, (3) Marketing and packaging. Both show similar weight loss results in clinical trials, with average weight loss of 15-25% depending on the study.